Theravance Biopharma (NASDAQ:TBPH) Price Target Raised to $15.00

Theravance Biopharma (NASDAQ:TBPH) had its price objective hoisted by TD Cowen from $13.00 to $15.00 in a research note released on Monday,Benzinga reports. TD Cowen currently has a hold rating on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright lifted their price target on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Oppenheimer lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. B. Riley Financial reaffirmed a “neutral” rating and issued a $14.00 price objective (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday, March 4th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a report on Thursday, January 22nd. Finally, Zacks Research upgraded shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Thursday, March 19th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Theravance Biopharma has an average rating of “Moderate Buy” and a consensus target price of $21.33.

Theravance Biopharma Trading Up 2.6%

Shares of NASDAQ:TBPH opened at $15.29 on Monday. The stock has a market capitalization of $787.28 million, a P/E ratio of 7.53 and a beta of 0.17. Theravance Biopharma has a 1-year low of $7.90 and a 1-year high of $21.03. The business has a 50-day moving average price of $17.69 and a two-hundred day moving average price of $16.89.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the sale, the senior vice president directly owned 232,699 shares of the company’s stock, valued at $3,248,478.04. This represents a 11.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 6.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Quarry LP acquired a new stake in Theravance Biopharma in the third quarter worth $26,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 1,411 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 515 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 781 shares in the last quarter. Finally, CIBC Private Wealth Group LLC increased its position in shares of Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 4,662 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.